Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB1 | P15086 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.69 |
| ▸ | POLB | P06746 | 4/20 | 0.69 |
| ▸ | MEN1 | O00255 | 4/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24209876 | 0.89 | KMT2A (0.83) | KMT2APOLBMEN1NPSR1TSHR | |
| SCHEMBL6279510 | 0.81 | KMT2A (0.73) | KMT2APOLBMEN1NPSR1TSHR | |
| SCHEMBL24029046 | 0.80 | TP53 (0.63) | CPB1KMT2APOLBMEN1TP53 | |
| SCHEMBL24029044 | 0.80 | ALDH1A1 (0.67) | KMT2AMEN1TP53NPSR1ALDH1A1 | |
| SCHEMBL24019597 | 0.79 | LMNA (0.74) | CPB1KMT2APOLBMEN1TP53 | |
| SCHEMBL6274384 | 0.78 | ALDH1A1 (0.64) | KMT2APOLBMEN1NPSR1TSHR | |
| SCHEMBL24210195 | 0.78 | KMT2A (0.73) | KMT2APOLBMEN1NPSR1TSHR | |
| SCHEMBL24209696 | 0.77 | NPSR1 (0.67) | KMT2APOLBMEN1NPSR1TSHR | |
| SCHEMBL8827928 | 0.76 | TP53 (1.00) | CPB1KMT2APOLBMEN1TP53 | |
| SCHEMBL24210088 | 0.75 | KMT2A (0.83) | KMT2AMEN1NPSR1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUND PROFESOR NOVOA SANTOS (ES) | 2023-06-15 | — | — | US | disclosed |
| WO-2021229035-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUNDACIÓN PROFESOR NOVOA SANTOS (ES) | 2021-11-18 | — | — | WO | disclosed |
| EP-3909577-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | Fundación Profesor Novoa Santos (ES) | 2021-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | XIAP, UBQLN1, MDM2 | CPB1 3243/4885KMT2A 663/4885POLB 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.